Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner

Keyphrases

• Tumor Growth 100%
• Estrogen Receptor 100%
• Receptor-independent 100%
• Malignant Peripheral Nerve Sheath Tumor (MPNST) 100%
• Tumor Cells 29%
• 4-hydroxytamoxifen 29%
• Neurofibromatosis Type I 11%
• Neurofibromatosis Type 1 (NF-1) 11%
• 17-estradiol 11%
• Tumor Cell Proliferation 11%
• Tumor Cell Survival 11%
• Mitogenesis 11%
• Clinical Observation 5%
• Clinical Trials 5%
• Antitumor Activity 5%
• Estrogen 5%
• Receptor-interacting Protein Kinase 1 (RIPK1) 5%
• Tumor Cell Lines 5%
• Ablation 5%
• Tumorigenesis 5%
• Therapeutic Potential 5%
• Tumor Proliferation 5%
• Tumor Cell Death 5%
• Biosynthetic Enzymes 5%
• Tumor Xenograft 5%
• Calmodulin 5%
• Plexiform Neurofibroma 5%
• Selective Estrogen Receptor Modulators 5%
• Steroidal 5%
• Malignancy-associated 5%
• G Protein-coupled 5%
• Trifluoperazine 5%
• Tamoxifen Sensitivity 5%
• ICI 182,780 5%
• Antiestrogen 5%
• Nerve Sheath Tumor 5%
• GPER1 5%
• Xenograft Growth 5%

Biochemistry, Genetics and Molecular Biology

• Tumor Progression 100%
• Estrogen Receptor 100%
• Cell Proliferation 40%
• Cell Survival 40%
• Mitogenesis 40%
• Estradiol 40%
• Enzyme 20%
• Clinical Trial 20%
• Antineoplastic Activity 20%
• Cell Death 20%
• Carcinogenesis 20%
• Estrogen Receptor Alpha 20%
• Trifluoperazine 20%
• G Protein 20%
• Calmodulin 20%
• G Protein-Coupled Estrogen Receptor 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Tumor Growth 100%
• Estrogen Receptor 100%
• Tamoxifen 100%
• Malignant Peripheral Nerve Sheath Tumor 100%
• Afimoxifene 29%
• Neurofibromatosis Type 1 11%
• Diethylstilbestrol 11%
• Clinical Trial 5%
• Carcinogenesis 5%
• Antitumor Activity 5%
• Guanine Nucleotide Binding Protein 5%
• Enzymes 5%
• Antiestrogen 5%
• Neurofibroma 5%
• Trifluoperazine 5%
• G Protein Coupled Receptor 30 5%
• Selective Estrogen Receptor Modulator 5%
• Nerve Sheath Tumor 5%
• Calmodulin 5%
• Estrogen 5%